Edition:
United States

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

7.63USD
22 Nov 2017
Change (% chg)

$0.06 (+0.79%)
Prev Close
$7.57
Open
$7.56
Day's High
$7.78
Day's Low
$7.49
Volume
948,385
Avg. Vol
1,623,363
52-wk High
$17.99
52-wk Low
$5.77

Summary

Name Age Since Current Position

Roger Kimmel

70 2007 Independent Chairman of the Board

Paul Campanelli

54 2016 President, Chief Executive Officer, Director

Blaise Coleman

43 2016 Chief Financial Officer, Executive Vice President

Antonio Pera

59 2016 President - Par Pharmaceutical

Terrance Coughlin

52 2016 Chief Operating Officer, Executive Vice President

Matthew Maletta

46 2015 Executive Vice President, Chief Legal Officer

Sharad Mansukani

48 2017 Director

Shane Cooke

54 2014 Independent Director

Nancy Hutson

67 2009 Independent Director

Michael Hyatt

71 Independent Director

William Montague

70 2009 Independent Director

Todd Sisitsky

45 2016 Independent Director

Jill Smith

59 2012 Independent Director

Biographies

Name Description

Roger Kimmel

Mr. Roger H. Kimmel is an Independent Chairman of the Board of Endo International Public Limited Company. is Chairman of the Board of Endo and is Chairman of Endo’s Nominating & Governance Committee and an alternate member of Endo’s Audit Committee and Operations Committee. Mr. Kimmel became Chairman of the Board upon the Company’s inception in February 2014. Mr. Kimmel has been Vice Chairman of Rothschild Inc., an investment banking firm, since January 2001. Previously, Mr. Kimmel was a partner of the law firm Latham & Watkins for more than five years. Mr. Kimmel is also a Director of PG&E Corporation, a public energy-based holding company and its subsidiary Pacific Gas and Electric Company, a utility company. Mr. Kimmel was a Director of Schiff Nutrition International until its sale in 2012, and was a Director and Chairman of Endo Health Solutions Inc. from July 2000 until February 2014. Mr. Kimmel also served as the Chairman of the Board of Endo Health Solutions Inc. during part of his tenure as Director. Mr. Kimmel served as Chairman of the Board of Trustees of the University of Virginia Law School Foundation (not-for-profit) from January 2009 to June 2015.

Paul Campanelli

Mr. Paul V. Campanelli serve as President, Chief Executive Officer, Director of the Company. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endo’s fully integrated U.S. Generics business, following Endo’s acquisition of Par Pharmaceutical. Prior to joining Endo, he had served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the company’s September 2012 acquisition by TPG. While CEO of Par, Mr. Campanelli built a strong leadership team and an industry-leading generics business. Under his leadership, the company significantly increased total revenue, acquired Michigan-based JHP Pharmaceuticals, established a business office in London to serve as Par’s entry point into the European generics market and completed its acquisition of an active pharmaceutical ingredients (API) facility located in Chennai, India. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical, Inc., the company’s generics division, from 2011 to 2012. Earlier in his tenure at Par, Mr. Campanelli held roles of increasing responsibility, including Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by Par’s board of directors. He also served on the board of directors of Sky Growth Holdings Corporation. Prior to joining Par, Mr. Campanelli served as Vice President, Business Development at Dr. Reddy’s Laboratories Ltd. where he was employed from 1992-2001. Mr. Campanelli earned his Bachelor of Science degree from Springfield College.

Blaise Coleman

Mr. Blaise Coleman serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Coleman was serving as Endo's Interim Chief Financial Officer since November 22, 2016. Mr. Coleman joined Endo in January 2015 as Vice President of Corporate Financial Planning & Analysis and was promoted to Senior Vice President of Global Finance Operations in November 2015. Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, a global biopharmaceutical company, latterly as the Chief Financial Officer of the AstraZeneca/Bristol-Myers Squibb US Diabetes Alliance from January 2013 until January 2015. Prior to this, he was the Head of Finance for the AstraZeneca Global Medicines Development organization based in Mölndal, Sweden from September 2011 to January 2013. Mr. Coleman joined AstraZeneca as Senior Director Commercial Finance for the US Cardiovascular Business in November 2007. He joined AstraZeneca from Centocor, a wholly owned subsidiary of Johnson & Johnson, where he held positions in the respective Licenses & Acquisitions and Commercial Finance organizations. Mr. Coleman’s move to Centocor in early 2003 followed 7 years’ experience with the global public accounting firm, PricewaterhouseCoopers LLP. He is a Certified Public Accountant. Mr. Coleman received a Bachelor of Science in accounting from Widener University and a MBA from Duke University, The Fuqua School of Business.

Antonio Pera

Mr. Antonio Pera is President - Par Pharmaceutical of the Company. In this role, Mr. Pera leads Endo’s U.S. Generics business including responsibility and oversight of Par Generic and Par Sterile sales teams, as well as Par’s marketing & business analytics group. Most recently, Mr. Pera served as Chief Commercial Officer of Par Pharmaceutical. He joined Par in February 2014 as part of Par’s acquisition of JHP Pharmaceutical, where he held a similar position. As Chief Commercial Officer, Mr. Pera was responsible for all sales, marketing, pricing and customer operations functions for Par. Prior to JHP and Par, Mr. Pera was Senior Vice President of Supply Chain Management for AmerisourceBergen (ABC), a major U.S. pharmaceutical wholesaler, for approximately five years. Prior to ABC, he held numerous senior leadership positions with generic drug companies including APP (now Fresenius Kabi), Bedford Laboratories and LyphoMed. Mr. Pera started his career as a sales representative for the parenteral products division of Baxter. Mr. Pera holds a B.S. in Business Administration from the University of Illinois in Champaign and an M.B.A. from DePaul University.

Terrance Coughlin

Mr. Terrance John Coughlin is Chief Operating Officer, Executive Vice President of the Company. In this role, Mr. Coughlin has responsibility for Manufacturing and Technical Operations, as well as Endo Ventures and R&D across the enterprise. Most recently, Mr. Coughlin served as Vice President, Operations of Par Pharmaceutical Companies, Inc., a subsidiary of Endo. Prior to Endo’s acquisition of Par in September 2015, Mr. Coughlin was the Chief Operating Officer of Par Pharmaceutical Companies, Inc. Prior to joining Par, Mr. Coughlin held a number of leadership roles with Glenmark Generics, Inc. USA/Glenmark Generics Limited latterly as the President and Chief Executive Officer of Glenmark Generics, Inc. USA/Glenmark Generics Limited. Prior to this, Mr. Coughlin had the overall responsibility for Glenmark’s North American, Western European and Eastern European generics businesses, as well as its global active pharmaceutical ingredient business and generics operations in India. Prior to joining Glenmark, Mr. Coughlin served as Senior Vice President at Dr. Reddy’s Laboratories, Inc. Mr. Coughlin began his career in 1988 with Wyckoff Chemical Company, Inc. Mr. Coughlin earned a B.S. in chemistry from Central Michigan University.

Matthew Maletta

Mr. Matthew Joseph Maletta is an Executive Vice President, Chief Legal Officer of Endo International Public Limited Company. Prior to joining Endo, Mr. Maletta served as Vice President, Associate General Counsel and Corporate Secretary of Allergan, Inc. In this position, he served as an advisor to the CEO and Board of Directors and supervised several large M&A transactions and takeover defense activities, including Allergan’s acquisition of Inamed and Actavis’ acquisition of Allergan. Mr. Maletta first joined Allergan in 2002 as Corporate Counsel and Assistant Secretary and during his tenure, held various roles of increased responsibility. Prior to joining Allergan, Mr. Maletta was in private practice, focusing on general corporate matters, finance, governance, securities and transactions. He holds a B.A. degree in political science from the University of Minnesota, summa cum laude, and a J.D. degree, cum laude, from the University of Minnesota Law School.

Sharad Mansukani

Dr. Sharad S. Mansukani, M.D. is Director of the company. He currently serves as a Senior Advisor to TPG Capital LP and on the Board of Directors of Kindred Healthcare, Inc. He previously served on the Board of Directors of IASIS Healthcare, Surgical Care Affiliates, IMS Health Holdings, Inc. and as Vice Chairman of the Board of Directors of HealthSpring, Inc. as well as a Strategic Advisor to the Board of Directors of Cigna Corporation. Additionally, Dr. Mansukani was a member of Medicare’s Program Advisory and Oversight Committee and served as a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services. Dr. Mansukani completed a residency and fellowship in ophthalmology at the University of Pennsylvania School of Medicine and a fellowship in quality management and managed care at the Wharton School of Business.

Shane Cooke

Mr. Shane M. Cooke is an Independent Director of Endo International Public Limited Company. He has been a member of the Board of Directors since July 2014 and is a member of Endo’s Audit Committee. He is currently President of Alkermes plc based in Dublin, Ireland upon completion of the merger between Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2011. Previously, he was head of EDT and Executive Vice President of Elan from 2007 through the Alkermes merger in 2011 and concurrently served as Chief Financial Officer of Elan Corporation from 2001 to May 2011. Mr. Cooke was appointed director of Elan in May 2005. Prior to joining Elan, he was Chief Executive of Pembroke Capital Limited, an aviation leasing company of which he was a founder. Mr. Cooke also previously held a number of senior positions in finance in the banking and aviation industries. Mr. Cooke is a chartered accountant and a graduate of University College Dublin, Ireland. He currently serves on the board of directors of Prothena Corporation plc, a publicly traded biotechnology company.

Nancy Hutson

Dr. Nancy J. Hutson, Ph.D., is Independent Directors of Endo International Public Limited Company., since 2009 . She is Chairman of Endo’s Operations Committee and a member of Endo’s Nominating & Governance Committee. Dr. Hutson retired from Pfizer, Inc. in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer’s pharmaceutical R&D site, known as Groton/New London Laboratories, the largest R&D site of any pharmaceutical company. At Pfizer, she led 4,500 colleagues (primarily scientists) and managed a budget in excess of $1 billion. She currently is a Director of BioCryst Pharmaceuticals, Inc. Dr. Huston previously served as Director of Cubist Pharmaceuticals until January 2015, and from March 2009 until February 2014, was a Director of Endo Health Solutions Inc. Dr. Hutson owns and operates Standing Stones Farm in Ledyard, CT, which is dedicated to supporting the equestrian sport of dressage.

Michael Hyatt

Mr. Michael Hyatt is an Independent Director of Endo International Public Limited Company. He has been a member of the Board of Directors since the Company’s inception in February 2014 and is a member of Endo’s Compensation Committee and an alternate member of the Nominating & Governance Committee. Mr. Hyatt is currently a Senior Advisor to Irving Place Capital, a leading institutional private equity firm focused on making equity investments in middle-market companies. Until 2008, Mr. Hyatt was a Senior Managing Director of Bear Stearns & Co., Inc. Mr. Hyatt previously served as a Director of Schiff Nutrition International until its sale in 2012. From July 2000 until February 2014, Mr. Hyatt was a Director of Endo Health Solutions Inc.

William Montague

Mr. William P. Montague, is Independent Director of Endo International Public Limited Company. since 2009. Mr. Montague is Chairman of Endo’s Compensation Committee, a member of Endo’s Audit Committee and an alternate member of Endo’s Nominating & Governance Committee. Mr. Montague served as Chief Executive Officer of Mark IV Industries, Inc., a leading global diversified manufacturer of highly engineered systems and components for transportation infrastructure, vehicles and equipment, from November 2004 until his retirement in July 2008 and as Director from March 1996. He joined Mark IV Industries in April 1972 as Treasurer/Controller, serving as Vice President of Finance from May 1974 to February 1986, then Executive Vice President and Chief Financial Officer from February 1986 to March 1996 and then as President from March 1996 to November 2004. Mr. Montague is also a Director of Gibraltar Industries, Inc., a publicly traded manufacturer and distributor of products for the building and industrial markets since 1993, and has served as Chairman of Gibraltar’s Board of Directors since June 2015. From February 2013 until May 2014, Mr. Montague served as a Director of Allied Motion Technologies Inc., a publicly traded company focused exclusively on serving the motion control market. From February 2009 until February 2014, Mr. Montague was a Director of Endo Health Solutions Inc.

Todd Sisitsky

Mr. Todd B. Sisitsky is Independent Director of the Company. Mr. Sisitsky is a Partner of TPG, the global alternative asset management firm. He is the Managing Partner of TPG Capital, co-head of the firm’s global healthcare investing platform, and a member of the firm’s Executive Committee. Mr. Sisitsky serves on the boards of directors of Adare Pharmaceuticals, IASIS Healthcare Corporation, Immucor Inc., and Surgical Care Affiliates, Inc. He previously served on the boards of directors of Aptalis Holdings, Inc. (formerly Aptalis Pharma, Inc.), Biomet Inc., HealthScope Ltd., Fenwal Inc., and Par Pharmaceuticals Companies, Inc. Mr. Sisitsky also serves on the Board of Overseers of the Dartmouth Medical School. Prior to joining TPG in 2003, Mr. Sisitsky worked at Forstmann Little & Company and Oak Hill Capital Partners. He received an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated summa cum laude.

Jill Smith

Ms. Jill D. Smith is an Independent Directors of Endo International Public Limited Company. since September 2012, She is a member of Endo’s Nominating & Governance Committee and Operations Committee and is an alternate member of the Audit Committee. Ms. Smith has been an international business leader for more than 25 years, including 16 years as a CEO of private and public companies in the technology and information services markets. Since March 2017, Ms. Smith has served as interim CEO of Allied Minds, a life sciences and technology commercialization company, where she has served as a Director since 2016. Previously, Ms. Smith was the Chairman, CEO and President of DigitalGlobe Inc., a leading provider of satellite imagery products and services to governments and companies worldwide. Ms. Smith is currently a Director and serves on the Board of Hexagon AB, a global pro- vider of design, measurement and visualization technologies, however, she will not stand for re-election to Hexagon AB’s Board at their annual general meeting in May 2017. She has also served on the corporate boards of SoundBite Communications, Inc., Germany-based Elster Group and DigitalGlobe (prior to her appointment as Chairman and CEO). Ms. Smith was a Director of Endo Health Solutions Inc. from September 2012 until February 2014.

Basic Compensation

Name Fiscal Year Total

Roger Kimmel

712,500

Paul Campanelli

8,492,910

Blaise Coleman

1,157,920

Antonio Pera

--

Terrance Coughlin

2,088,990

Matthew Maletta

2,076,790

Sharad Mansukani

--

Shane Cooke

480,000

Nancy Hutson

522,500

Michael Hyatt

522,500

William Montague

542,500

Todd Sisitsky

--

Jill Smith

492,500
As Of  30 Dec 2016